Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.

On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19.

5 days ago · Regeneron's strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts expected to drive growth. The company anticipates 2026 as a …

Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing life-transforming medicines for people with serious diseases.

4 days ago · The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

Jan 11, 2026 · The story around Regeneron is shifting, and one big player just made it official.

We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® (RGC) and pioneering genetic medicine platforms, enabling us to identify innovative targets …

6 days ago · Regeneron Pharmaceuticals, Inc. (REGN) 44th Annual J.P. Christopher Schott JPMorgan Chase & Co, Research Division Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's …

Oct 29, 2025 · Explore Regeneron’s pipeline of investigational medicines advancing through clinical trials for a range of serious diseases.

3 days ago · Day 4 of the JP Morgan Healthcare Conference newsletter features a chat with Regeneron’s George Yancopoulos, an IPO forecast, and a big immunology question.